The new vaccine candidates studied in the trial in 1,234 participants 56 years of age and older elicited substantially higher neutralizing antibody responses against Omicron BA.1 when compared to the companies’ current COVID-19 vaccine.

Earlier, Moderna published data on its booster vaccine which it said is well effective against subtypes of Omicron and induces a strong immune response.